Cargando…
COVID-19-associated opportunistic infections: a snapshot on the current reports
Treatment of the novel Coronavirus Disease 2019 (COVID-19) remains a complicated challenge, especially among patients with severe disease. In recent studies, immunosuppressive therapy has shown promising results for control of the cytokine storm syndrome (CSS) in severe cases of COVID-19. However, i...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381864/ https://www.ncbi.nlm.nih.gov/pubmed/34424451 http://dx.doi.org/10.1007/s10238-021-00751-7 |
_version_ | 1783741442153250816 |
---|---|
author | Abdoli, Amir Falahi, Shahab Kenarkoohi, Azra |
author_facet | Abdoli, Amir Falahi, Shahab Kenarkoohi, Azra |
author_sort | Abdoli, Amir |
collection | PubMed |
description | Treatment of the novel Coronavirus Disease 2019 (COVID-19) remains a complicated challenge, especially among patients with severe disease. In recent studies, immunosuppressive therapy has shown promising results for control of the cytokine storm syndrome (CSS) in severe cases of COVID-19. However, it is well documented that immunosuppressive agents (e.g., corticosteroids and cytokine blockers) increase the risk of opportunistic infections. On the other hand, several opportunistic infections were reported in COVID-19 patients, including Aspergillus spp., Candida spp., Cryptococcus neoformans, Pneumocystis jiroveci (carinii), mucormycosis, Cytomegalovirus (CMV), Herpes simplex virus (HSV), Strongyloides stercoralis, Mycobacterium tuberculosis, and Toxoplasma gondii. This review is a snapshot about the main opportunistic infections that reported among COVID-19 patients. As such, we summarized information about the main immunosuppressive agents that were used in recent clinical trials for COVID-19 patients and the risk of opportunistic infections following these treatments. We also discussed about the main challenges regarding diagnosis and treatment of COVID-19-associated opportunistic infections (CAOIs). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10238-021-00751-7. |
format | Online Article Text |
id | pubmed-8381864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-83818642021-08-23 COVID-19-associated opportunistic infections: a snapshot on the current reports Abdoli, Amir Falahi, Shahab Kenarkoohi, Azra Clin Exp Med Review Article Treatment of the novel Coronavirus Disease 2019 (COVID-19) remains a complicated challenge, especially among patients with severe disease. In recent studies, immunosuppressive therapy has shown promising results for control of the cytokine storm syndrome (CSS) in severe cases of COVID-19. However, it is well documented that immunosuppressive agents (e.g., corticosteroids and cytokine blockers) increase the risk of opportunistic infections. On the other hand, several opportunistic infections were reported in COVID-19 patients, including Aspergillus spp., Candida spp., Cryptococcus neoformans, Pneumocystis jiroveci (carinii), mucormycosis, Cytomegalovirus (CMV), Herpes simplex virus (HSV), Strongyloides stercoralis, Mycobacterium tuberculosis, and Toxoplasma gondii. This review is a snapshot about the main opportunistic infections that reported among COVID-19 patients. As such, we summarized information about the main immunosuppressive agents that were used in recent clinical trials for COVID-19 patients and the risk of opportunistic infections following these treatments. We also discussed about the main challenges regarding diagnosis and treatment of COVID-19-associated opportunistic infections (CAOIs). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10238-021-00751-7. Springer International Publishing 2021-08-23 2022 /pmc/articles/PMC8381864/ /pubmed/34424451 http://dx.doi.org/10.1007/s10238-021-00751-7 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Article Abdoli, Amir Falahi, Shahab Kenarkoohi, Azra COVID-19-associated opportunistic infections: a snapshot on the current reports |
title | COVID-19-associated opportunistic infections: a snapshot on the current reports |
title_full | COVID-19-associated opportunistic infections: a snapshot on the current reports |
title_fullStr | COVID-19-associated opportunistic infections: a snapshot on the current reports |
title_full_unstemmed | COVID-19-associated opportunistic infections: a snapshot on the current reports |
title_short | COVID-19-associated opportunistic infections: a snapshot on the current reports |
title_sort | covid-19-associated opportunistic infections: a snapshot on the current reports |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381864/ https://www.ncbi.nlm.nih.gov/pubmed/34424451 http://dx.doi.org/10.1007/s10238-021-00751-7 |
work_keys_str_mv | AT abdoliamir covid19associatedopportunisticinfectionsasnapshotonthecurrentreports AT falahishahab covid19associatedopportunisticinfectionsasnapshotonthecurrentreports AT kenarkoohiazra covid19associatedopportunisticinfectionsasnapshotonthecurrentreports |